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K polyomavirus infection in transplanted kidneys
that leads to BK virus–associated nephropathy
(BKVAN) is an important cause of allograft loss and
has limited treatment options.1 Recent data suggest
that BK viremia affects approximately 10% of people
within the first 12 months following kidney transplan-
tation.2 Among recipients with BKVAN, the overall
risk of allograft loss is substantially increased, esti-
mated to be 50% within 5 years of diagnosis.
Geographic variation in the rates of BK infection also
has been recognized. Depending on local epidemiology
and immunosuppression practices, the prevalence of
viruria, viremia, and histological features of BKVAN
is reported to be between 35% and 40%, 12% and
15%, and 3% and 8%, respectively.3
Early detection of BK viremia through screening
may allow judicious reduction in immunosuppression
dose preventing the detrimental effects of BKVAN,
such as premature allograft loss. Current screening
methods are highly variable between centers and
include a combination of quantitative detection of BKInternational Reports (2020) 5, 1777–1790DNA in whole blood (BK viremia) using real-time po-
lymerase chain reaction assay or the detection of BK
viruria. The Kidney Disease Improving Global Out-
comes 2009 guidelines for the care of kidney transplant
recipients recommended routine monthly screening for
BK viremia using BK nucleic acid testing for the first 3
to 6 months and then 3 monthly thereafter for the first
year post transplantation.4
Observational data also suggest a higher number of
BK copies detected (BK viral load) is associated with an
increased risk of BKVAN. Prior studies have indicated a
test threshold of 1  104 viral copies per milliliter has a
test specificity and sensitivity for BKVAN of 95.0 (77.5–
99.7) and 83.4 (78.4–84.7), respectively, with positive
and negative predictive values of 61.9 (50.5–64.9) and
98.3 (92.4–99.9), assuming an overall prevalence of 5%.5
A single-center study reported reduction in immuno-
suppression may result in decrease in the BK viral load
and a concomitant decrease in the risk of BKVAN,6 but
the optimal treatment strategies are uncertain. Trials of
prophylactic treatment with quinolones also showed1777
Table 1. Baseline characteristics of the survey participants
Demographics, n (%) N [ 113
Male 71 (63)
Female 38 (34)
Prefer not to say 4 (3)





$ 60 8 (7.1)
State/Territorya
Australian Capital Territory 4 (4.4)
New South Wales 39 (43.3)
Northern Territory 3 (3.3)
Queensland 15 (16.7)
South Australia 4 (4.4)
Tasmania 1 (1.2)
Victoria 19 (21.1)
West Australia 5 (5.6)











an ¼ 23 did not provide details of which states they reside in.
bn ¼ 4 did not provide details of their practice location.
RESEARCH LETTERSlack of treatment efficacy in the prevention of disease.7
The current options include complete withdrawal of the
antimetabolites, or switching from mycophenolate
mofetil (MMF) to azathioprine, 50% dose reduction in
calcineurin inhibitors, conversion from tacrolimus to
ciclosporin, introduction of mammalian target of rapa-
mycin inhibitors, or replace antimetabolite agents with
leflunomide.1 Once BKVAN develops, current treatment
regimens are limited and largely unproven, beyond
reducing the intensity of immunosuppression, as
described previously. Recent work has shown possible
benefits in the clearance of BK viruses from blood and
renal tissues with i.v.Ig and the antiviral agent cidofo-
vir, but this is limited to a single-center study.2 To better
understand the current screening and management
patterns for BK viremia and BKVAN, and to inform the
design of a multicenter randomized controlled inter-
vention trial in the management of BK infection in kid-
ney transplant recipients, we conducted a survey among
relevant Australian and New Zealand clinicians.
RESULTS
Of the 557 practicing nephrologists in Australia and
New Zealand, 113 (20.2%) completed the survey. The1778baseline characteristics of the respondents are shown in
Table 1. Most respondents were men (n ¼ 73, 61%),
aged 40 years and older (n ¼ 82, 72.6%), had more than
10 years of experience in nephrology (n ¼ 66, 58.4%),
worked in a transplanting unit (n ¼ 68, 62.4%), and
lived in Australia (n ¼ 93, 82.3%). The Australian and
New Zealand Society of Nephrology and the Trans-
plantation Society of Australia and New Zealand male
membership is approximately 55% to 60%. This is
consistent with the gender distribution of the survey.
Reported 1-Year Incidence of BK Viremia and
BKVAN in Kidney Transplant Recipients
Table 2 shows the reported incidence, screening, and
management strategies of BK infection in kidney
transplant recipients. Approximately 50% of re-
spondents reported an estimated incidence of BK
viremia of approximately 10% to 20% and 1% to 3%
for BKVAN.
Screening Practices for BK Viremia
There was substantial variability in reported screening
practices. The most common screening modality was
BK quantitative real-time polymerase chain reaction on
plasma (80%). The use of urine viruria and decoy cells
was much less frequent (less than 10%). The frequency
of screening varied between monthly (27%) to 3-
monthly (18%) within the first 12 months of trans-
plantation, typically with more frequent screening in
the first 3 months posttransplant. Approximately 10%
of nephrologists stated they do not routinely perform
screening; however, once persistent viremia was
detected, 30% would perform allograft biopsy to
exclude BKVAN, whereas most (approximately 70%)
would consider a biopsy only when graft dysfunction
occurred.
Management Strategies of BK Viremia and
BKVAN
Most respondents reported that they would reduce the
dose of immunosuppressive drugs (70%) in recipients
with persistent BK viremia. Reduction in the doses of
calcineurin inhibitors and antimetabolites (such as
MMF) was the first-line practice for most respondents
(n ¼ 75, 66.4%), followed by a switch to alternative
calcineurin inhibitors (tacrolimus to cyclosporine) and
antimetabolite therapy (such from MMF to leflunomide,
or MMF to azathioprine) (n ¼ 34, 30%), then changing
from MMF to leflunomide (n ¼ 30, 26.5%) without
altering calcineurin inhibitor doses, followed by alter-
ation to a combination of low-dose tacrolimus and
mammalian target of rapamycin inhibitors (n ¼ 9, 8%).
Once BKVAN developed, a range of adjuvant treatment
options were available to the respondents. CidofovirKidney International Reports (2020) 5, 1777–1790
Table 2. Reported incidence, screening, and management
strategies of BK viral infection in kidney transplant recipients (n¼ 113)
Incidence of BK viremia, n (%)




No response 10 (8.9)




No response 11 (9.7)
Frequency of screening, n (%)
Monthly 30 (26.6)
Every second month 10 (8.6)
Every 3 months 20 (17.7)
Every 6 months 2 (1.8)
Never 12 (10.6)
Other 29 (25.7)
No response 10 (8.9)
Types of screening, n (%)a
Urine decoy cells 6 (5.3)
Real-time plasma BK polymerase chain reaction 90 (80)
Urinary viral load 14 (12.3)
Performance of kidney biopsy to exclude
BKVAN, n (%)a
Presence of viruria and no viremia 0 (0)
Presence of viremia only 29 (25.7)
Presence of graft dysfunction 78 (69)
Presence of graft dysfunction and viremia 80 (71)
Scenarios which reduction in immunosuppression are
considered, n (%)a
Persistent BK viruria without viremia 11 (9.7)
Persistent BK viremia without graft dysfunction 76 (67.3)
Persistent BK viremia with allograft dysfunction 81 (71.7)
Presence of biopsy-proven BKVAN 85 (75.2)
Reduction in immunosuppression in the presence of
viremia, n (%)a
Reduction in tacrolimus and MMF dose 76 (67.2)
Change to an alternative CNI and antimetabolites 37 (32.7)
Change from CNI to mTORIs 14 (12.4)
Change to low-dose CNI and mTORIs 20 (17.7)
Change from MMF to leflunomide only 30 (26.5)
Use of adjuvant treatment options when BKVAN was
diagnosed, n (%)
Quinolones
Practice routinely 5 (4.4)
Consider only in some patients 27 (23.9)
Do not use 61 (54.0)
No response 20 (17.7)
Cidofovir
Practice routinely 11 (9.7)
Consider only in some patients 38 (33.6)
Do not use 44 (38.9)
No response 20 (17.7)
i.v.Ig
Practice routinely 16 (14.1)
Consider only in some patients 55 (48.7)
Do not use 22 (19.5)
No response 20 (17.7)
(Continued in the next column)
Table 2. (Continued)
Trial participation, n (%)
Yes 77 (68.1)
No 14 (12.4)
No response 22 (19.5)
BKVAN, BK viral associated nephropathy; CNI, calcineurin inhibitors; MMF, mycophe-
nolate mofetil; mTORIs, mammalian target of rapamycin inhibitors
aNot mutually exclusive.
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Kidney International Reports (2020) 5, 1777–1790and i.v.Ig were considered in some patients and most
did not recommend the use of quinolones. Most ne-
phrologists (68%) agreed they would participate in a
multicenter intervention trial of BK infection in kidney
transplant recipients.DISCUSSION
This binational survey suggests that BK viral infection is
an important early posttransplant complication in kid-
ney transplant recipients. The reported incidence of BK
viremia and BKVAN appear to be consistent across
Australia and New Zealand, varying between 10% and
15% for viremia and up to 3% for BKVAN. Routine BK
polymerase chain reaction testing is the most common
screening modality used, but inconsistencies exist be-
tween the reported screening frequencies and the in-
ternational recommended guidelines.4 In most
circumstances, persistent viremia with an elevation in
serum creatinine would prompt a diagnostic biopsy to
detect BKVAN and exclude other or concurrent causes
of allograft dysfunction. Although modification of
immunosuppression is universal for all participating
units, there is considerable variability in the approaches
used to achieve this. More than two-thirds of the ne-
phrologists would reduce the doses of immunosup-
pressive drugs in the presence of BK viremia or BKVAN,
and although there is a wide variation in the immuno-
suppression reduction strategy, reduction in the total
dose of tacrolimus and MMF remains the most favored
approach. Adjuvant treatments are not routinely used
by the respondents in the treatment of BKVAN, but 43%
and 63% would consider prescribing cidofovir and
i.v.Ig, , respectively, when other options have failed, or
graft function is deteriorating rapidly.
BKVAN remains an important cause of allograft
failure in kidney transplant recipients. Despite the
high prevalence of BK viremia and the established
association between BK viremia and development of
BKVAN, the lack of clinical evidence to guide man-
agement is likely responsible for the variety of man-
agement strategies used, as reported in this survey.
Reducing immunosuppression remains the mainstay
treatment for BK viremia and BKVAN, but the optimal1779
RESEARCH LETTERSapproach to reducing or substituting immunosup-
pressive agents remains uncertain. In this survey,
knowledge of the incidence of BK infection and the
variability between sites will inform the design of a
health care–embedded platform trial. More impor-
tantly, we have collected the information to conduct a
process of research prioritization, in consultation with
consumer groups, to define platform objectives that
evaluate key intervention strategies and treatment
arms that are currently preferred and commonly used
by nephrologists. As most respondents to this survey
supported the conduct of a randomized controlled
trial to address this research question, a collaborative
multicenter clinical study in Australia and New Zea-
land with a pragmatic trial design is a unique op-
portunity to address some of these evidence gaps and
to inform future clinical management of recipients
with BK viremia or BKVAN.DISCLOSURE
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n the United States, nearly half of pregnancies are
unintended,1 and unintended pregnancy is associ-
ated with preterm birth and low birth weight.2
Glomerular disease and vasculitis increase risk ofadverse obstetric outcomes including preeclampsia,
preterm delivery, and perinatal death.3 Preventing
unintended pregnancy in this high-risk group is
imperative, and requires proactive family planningKidney International Reports (2020) 5, 1777–1790
